Introduction:
Boehringer Ingelheim announced a US$260 million investment into a new Biological Development Center (BDC) at the company’s Research and Development site in Biberach, Germany.
Features:
The BDC will help to maximise by integrating Biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit. It provides about 100 member employment at the new BDC.
The BDC is expected to be operational by 2020.
New Biologicals Development Center majorly focuses on therapeutic areas with high unmet medical need such as cancer and immunological diseases.
The BDC will help to maximise by integrating Biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit.
The BDC will be particularly driven by two core areas, immune oncology and immunology.
The new building will employ about 100 new employees.
The BDC is expected to be operational by 2020.
Specifications:
| Name | Boehringer Ingelheim |
| Location | Biberach, Germany |
| Type | Construction |
| Schedule | To be operational by 2020 |
